“…These include blood assays to monitor tumor burden (13,14), immunohistochemical analyses of tissue samples to detect tumor cells (15,16), tumor imaging with radiolabeled MAbs (17,18), and MAb-guided therapy (19,20). Since more than 20 structurally related antigens, such as nonspecific cross-reacting antigen (NCA) (21,22), normal fecal antigen (NFA) (23,24,25,26), or biliary glycoprotein (BGP) (27), have been found in various human tissues or body fluids as products of the CEA gene family members (5), elucidation of the specificity of anti-CEA MAbs is very important. Their specificity has been evaluated by several approaches including the analysis of cross-reactivity with the CEA-related antigens (28,29,30), immuno-histochemical reactivity with a variety of normal or malignant tissues (31,32,33), and competitive binding activity among MAbs (29,30,34).…”